ARCHIVES

In Brief: Yarbro To Leave As NCI Centers Chief to Head Missouri Cancer Program; Replaced By Cantril

This article is from The Cancer Letter archive.

Vol. 01 No. 22 | May 30, 1975

Download PDF Visit The Full Archive

Related Articles

In Brief: Deisseroth Leaves M.D. Anderson To Head Yale’s Oncology, Gene Therapy Programs

September 15, 1995

Calcitrol+Docetaxel Prolongs Survival In Prostate Cancer

June 24, 2005

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009

DCT Board Approves Concepts Of Five Contract Recompetitions

October 14, 1983

DRCCA Board Votes To End Support For CCPDS July 31, 1983

May 14, 1982

Revlimid Maintenance Therapy Delayed Progression by 90%

May 27, 2011